GDF Suppliers
Responding to changes in the TB drug market, especially price increases and bottlenecks in the supply of key active pharmaceutical ingredients for first-line TB drugs, the GDF issued a new tender for drug manufacturers in March 2005.
As a result of this tender, which closed in April 2005, the four (4) manufacturers listed below were contracted under Long Term Agreements to supply GDF drugs and related commodities. Click here to read the briefing note on the results of the GDF tender.
Svizera Europe (SE) - Svizera Labs Pvt Ltd (India)
Svizera Europe, headquartered in the Netherlands, supplies first line anti-TB drugs from its manufacturing facility, Svizera Pvt Labs Ltd, in Mumbai, India. Svizera Europe was set up as the result of a reorganization of the Medical Export Group which has been a reliable supplier of a broad selection of medicines and medical products for world-wide export to basic healthcare projects for over 20 years.
Visit: http://www.svizera.org/ or http://www.svizera.com/ for more information or contact: Mr Boudewijn Ploos van Amstel/E-mail: Amstel@svizera.org
Lupin
Lupin is one of the largest manufacturers of drugs that combat tuberculosis, bacterial infections, and cardiovascular disease. Lupin has been a pioneer and market leader in the global supply of first line TB drugs, which are manufactured at it plant in Aurangabad, India.
Visit: http://www.lupinworld.com/ for more information or contact: Mr Andrew Macaulay/Email: andrew@lupineurope.com
Cadila
A research based life sciences pharmaceutical company of India, Cadila manufactures formulations for human, veterinary, active pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, biosynthesis, genetic engineering, vaccines, immunoglobulins. Cadila's manufacturing plant for TB drugs is located in Ahmedabad, India.
Visit: http://www.cadilapharma.com/ for more information or contact: Mr J. Parswani - President, International Business/E-mail: jparswani@cadilapharma.co.in
Strides-Sandoz
Strides- Sandoz is a successful partnership between a multi-national and an emerging global pharmaceutical company which is committed to fighting global scourges – TB, HIV/AIDS and Malaria. The partnership offers advantages of global research at competitive manufacturing costs. Strides’ manufacturing site at Bangalore is pre-qualified for certain anti-TB products and anti-retroviral medicines by WHO. The site has also received approval from the US Food and Drug Administration (US FDA). The partnership is supported by robust Research & Development and Distribution networks spanning more than 55 countries.
Visit: http://www.stridesarco.com/ for more information.
|
